Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection

• Status: Unknown status
• Trial end date: 2018-07-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is a prospective non-randomized controlled study. The purpose of this study is to evaluate the validity and safety of sorafenib and transcatheter arterial chemoembolization (TACE) for microvascular invasion (MVI) in hepatocellular carcinoma (HCC) patients after radical surgery.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese Academy of Medical Sciences
• Treatments: Niacinamide; Sorafenib

Criteria

Inclusion Criteria:

• 18-75 years of age;

• The liver tumor has been radically resected;

• Postoperative pathology proved to be hepatocellular carcinoma with negative margin and microvascular invasion;

• Imaging evaluations(CT/MRI) were performed at 1 month after the resection and no area of enhancement was seen;

• Child-Pugh A;

• Eastern Cooperative Oncology Group(ECOG) body condition score (PS) 0-1;

• Then patients understand and voluntarily signed a written informed consent;

Exclusion Criteria:

• Recurrent HCC;

• pathology-proved multifocal HCC or HCC with satellite nodules;

• Tumor thrombus in portal vein or inferior vena cava trunk;

• Patients with extrahepatic metastasis found by radiologic or pathologic examination;

• severe dysfunction of the heart, kidney, or other organs.The patients cannot tolerate TACE or sorafenib after general assessment of the situation;

• Enrolled in other clinical study at the same time;

• Previously treated with other antitumor treatments except the resection;

• The researchers believe that the patient does not fit this study;

• Pregnant or lactating women.